Shots:

• The first patient has been dosed in the combination part of the P-Ib/IIa study to evaluate tasquinimod + IRd as antimyeloma agents in patients with r/r MM. The study is being conducted with the Abramson Cancer Center of the University of Pennsylvania
• The 2EPs will include antimyeloma activity. In previous studies, tasquinimod monothx. was generally well tolerated & established treatment schedule along with safety profile of tasquiniomod
• The results also showed a clear therapeutic potential in preclinical models as monothx. and in combination with standard multiple myeloma therapy. Tasquinimod is being developed as a new immunomodulatory treatment for hematological malignancies in MM

to­Ref: Globenewswire | Image: Huntington's Disease News